HomeAbout

TL;DR CNBC


Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump - TL;DR CNBC

Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump

Publishing timestamp: 2024-03-27 08:46:46


Summary

Moderna announced positive clinical trial data on three experimental vaccines, moving them to final stage studies. The update brings the biotech company closer to having multiple products on the market, addressing a need for more vaccines beyond Covid. The company also discussed its future plans during its investor event, focusing on vaccines for other viruses such as norovirus, Epstein-Barr virus, and shingles. Moderna's stock rose after the announcements, and the company is also working on combination vaccines and flu shots. They have entered into a funding agreement with Blackstone Life Sciences to advance their flu shot program. The company's mRNA technology is showing promise in developing vaccines for various diseases, with significant opportunities ahead.


Sentiment: POSITIVE

Tickers: MRNA

Keywords: business newsscienceimmunizationsvaccinationscenters for disease control and preventionbusinessmoderna inchealth care industrypharmaceuticalsbiotechnologybiotech and pharmaceuticals

Source: https://www.cnbc.com/2024/03/27/moderna-moves-three-vaccines-into-final-stage-trials.html


Developed by Leo Phan